Nektar Therapeutics sees its stock nearly double after announcing positive Phase IIb data for its lead pipeline candidate, rezpegaldesleukin (rezpeg), in atopic dermatitis (AD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results